MIP-3/CCL23
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P55773 |
---|---|
Species | Human |
Sequence | Arg22-Asn120 |
Purity | > 97% as analyzed by SDS-PAGE > 97% as analyzed by HPLC |
Endotoxin Level | < 1 EU/ µg of protein by LAL method |
Biological Activity | Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human T-lymphocytes is in a concentration of 10.0-50.0 ng/ml. |
Expression System | E. coli |
Theoretical Molecular Weight | 11.4 kDa |
Formulation | Lyophilized from a 0.2 µm filtered solution in 20 mM PB, pH 7.4, 150 mM NaCl. |
Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. |
Storage & Stability | Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
Gene ID | 6368 |
---|---|
Other Names | C-C motif chemokine 23, CK-beta-8, CKB-8, Macrophage inflammatory protein 3, MIP-3, Myeloid progenitor inhibitory factor 1, MPIF-1, Small-inducible cytokine A23, CCL23(19-99), CCL23(22-99), CCL23(27-99), CCL23(30-99), CCL23, MIP3, MPIF1, SCYA23 |
Target Background | MIP-3/CCL23 is a CC chemokine that signals through the CCR1 receptor. MIP-3 chemoattracts monocytes, resting T-lymphocytes and neutrophils, but does not chemoattract activated lymphocytes. Additionally, MIP-3 has been shown to inhibit colony formation of bone marrow myeloid immature progenitors. Alternative splicing of the MPIF1 gene results in two mRNAs that encode a short (CKβ8) and a long (CKβ81) isoform of the chemokine. CKβ8 cDNA encodes a 120 amino acid (aa) residue precursor protein with a putative 21 aa residue signal peptide that is cleaved to generate a 99 aa residue mature CKβ8 (aa 22 120). Additional N terminal processing of the 99 aa residue variant can generate a 75 aa residue CKβ8 (aa 46 120) that is significantly more active than the 99 aa residue variant. |
Name | CCL23 |
---|---|
Synonyms | MIP3, MPIF1, SCYA23 |
Function | Shows chemotactic activity for monocytes, resting T- lymphocytes, and neutrophils, but not for activated lymphocytes. Inhibits proliferation of myeloid progenitor cells in colony formation assays. This protein can bind heparin. Binds CCR1. CCL23(19-99), CCL23(22-99), CCL23(27-99), CCL23(30-99) are more potent chemoattractants than CCL23. |
Cellular Location | Secreted. |
Tissue Location | High levels in adult lung, liver, skeletal muscle and pancreas. Moderate levels in fetal liver, adult bone marrow and placenta. The short form is the major species and the longer form was detected only in very low abundance. CCL23(19-99), CCL23(22-99), CCL23(27-99), CCL23(30-99) are found in high levels in synovial fluids from rheumatoid patients. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.